S-ABS01-113

S-ABS01-113 is a small molecule research compound developed as a potential treatment for opioid use disorder (OUD). It acts as a highly selective and efficacious dopamine D3 receptor (D3R) partial agonist, exhibiting over 1000-fold selectivity for D3R compared to the D2 receptor. Chemically, it is the S-enantiomer of the racemic mixture (±)-ABS01-113 and a structural analog of VK4-40, featuring a fluorine substitution in the linking chain. Developed through collaboration between Johns Hopkins Drug Discovery and the National Institute on Drug Abuse (NIDA), S-ABS01-113 has demonstrated the ability to attenuate heroin-seeking behavior and self-administration in preclinical rodent models without affecting baseline locomotor activity, suggesting high translational potential for addiction therapy.

Other names

(S)-enantiomer of (±)-ABS01-113